Article
PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.
Life science alliance - 1 Dec 2024
Gazzeri Sylvie, Zubchuk Nadiia, Montaudon Elodie, Nemati Fariba, Huot-Marchand Sarah, Berardi Giulia, Pucciarelli Amelie, Dib Yassir, Nerini Dylan, Oddou Christiane, Pezet Mylène, David-Boudet Laurence, Ardin Camille, de Fraipont Florence, Maraver Antonio, Girard Nicolas, Decaudin Didier, Toffart Anne-Claire, Eymin Beatrice
Abstract excerpt
Despite initial high response rates to first-line EGFR TKI, all non-small-cell lung cancer (NSCLC) with EGFR-activating mutation will ultimately develop resistance to treatment. Identification of resistance mechanisms is critical to adapt treatment and improve patient outcomes. Here, we show that a PPP3CB transcript that encodes full-length catalytic subunit 2B of calcineurin accumulates in EGFR-mutant NSCLC...
Topics
Join the communities discussing this publication.